10-Q: OpGen Pivots to FinTech, Reports Q2 Profit Surge Amid Nasdaq Delisting
Quarterly Report
OpGen, Inc. reported a significant turnaround to profitability in Q2 2025, driven by its strategic pivot to financial services and technology, despite its recent delisting from Nasdaq.
Summary
- OpGen has strategically repositioned itself from a precision medicine company to the financial services and technology industry, primarily through its new wholly-owned subsidiary, CapForce International Holdings Ltd.
- The company reported a net income of $3,509,992 for the three months ended June 30, 2025, a substantial improvement from a net loss of $1,576,349 in the same period of 2024.
- Total revenue for the three months ended June 30, 2025, surged to $4,000,000, entirely from listing sponsorship services, compared to $28,000 in the prior year.
- Operating expenses significantly decreased by approximately 62% to $597,225 for the three months ended June 30, 2025, due to scaling down legacy operations.
- OpGen was delisted from Nasdaq on August 8, 2025, and its shares now trade on the OTC Markets Group Expert Market, with plans to reapply for Nasdaq listing.
- The company has access to up to $7.0 million in additional common stock sales to AEI Capital Ltd. until December 31, 2025, to fund operations.
- CapForce entered a Joint Venture Agreement with European Credit Investment Bank (ECIB) in April 2025 to develop stock trading and digital investment banking platforms.
Sentiment
Score: 7
Explanation: The company achieved a significant turnaround to profitability and revenue growth due to its strategic repositioning. However, the Nasdaq delisting and high customer concentration introduce notable risks and uncertainties, tempering the overall positive sentiment.
Positives
- Achieved a significant turnaround to net income of $3,509,992 for the three months ended June 30, 2025, compared to a net loss of $1,576,349 in the prior year.
- Revenue increased substantially to $4,000,000 for the three months ended June 30, 2025, from $28,000 in the same period of 2024, driven by new listing sponsorship services.
- Operating expenses decreased by approximately 62% for the three months ended June 30, 2025, reflecting successful scaling down of legacy operations.
- Management believes current cash and access to $7.0 million from AEI Capital Ltd. will fund operations for over 12 months, addressing going concern issues.
- Formation of CapForce and the joint venture with ECIB represent a strategic pivot into potentially high-growth financial services and technology sectors.
Negatives
- Delisted from The Nasdaq Stock Market LLC on August 8, 2025, moving to the OTC Markets Group Expert Market, which may impact liquidity and investor perception.
- Cash and cash equivalents decreased to $831,634 as of June 30, 2025, from $1,310,653 at December 31, 2024.
- Reliance on financing arrangements with AEI Capital Ltd., a controlling shareholder, for future funding.
- The $5.0 million investment in equity securities of a privately held client is subject to significant judgment and market risk, and its fair value is not based on observable inputs.
- One customer represented 100% of total revenues for the three and six months ended June 30, 2025, indicating high customer concentration risk.
Risks
- Liquidity and working capital requirements, including cash requirements over the next 12 months.
- Ability to execute upon and achieve the benefits of the strategic direction under new leadership and Board of Directors.
- Ability to identify and realize the benefits of potential strategic transactions.
- Adverse effects on business condition and results of operations from general economic and market conditions and overall fluctuations in the United States and international markets, including deteriorating market conditions due to investor concerns regarding inflation.
- Development of a market for common stock, which is currently quoted on the OTC Expert Market and eligible only for unsolicited quotes, resulting in the absence of market makers.
- If common stock is traded on a market other than the OTC Expert Market and a market develops, actions by third parties to either sell or purchase common stock in quantities may have a significant effect on stock price.
- Compliance with U.S. regulations applicable to the business.
- Expectations regarding future revenue and expenses.
- No assurance that the company will be able to relist with The Nasdaq Stock Market LLC.
- The investment in equity securities of a privately held entity is subject to significant judgment and market risk and is not based on observable inputs.
- High customer concentration, with one customer representing 100% of total revenues for the three and six months ended June 30, 2025.
Future Outlook
The company anticipates funding its operations primarily through financing arrangements with AEI Capital Ltd. and plans to apply for relisting with The Nasdaq Stock Market LLC after meeting relevant listing requirements. CapForce, the new subsidiary, contemplates entering the financial technology industry supporting digital investment banking activities, cross-border securities trading, advanced computational model-enabled investment banking advisory, asset management services, and capital table management. The joint venture with ECIB aims to develop stock trading and digital investment banking platforms across Asia and globally.
Management Comments
- "We believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements."
- "We anticipate funding our operations primarily through financing arrangements with AEI Capital Ltd, including the August 2024 Securities Purchase Agreement noted above, until our operating business is able to sustain our operations."
- "We intend to use financing opportunities strategically to continue strengthening our financial position."
- "We plan to apply for relisting with The Nasdaq Stock Market LLC after meeting the relevant Nasdaq listing requirements."
Industry Context
OpGen's strategic pivot from precision medicine to financial services and technology, particularly digital investment banking and listing sponsorship, aligns with broader trends of FinTech innovation and the increasing demand for specialized advisory services in global capital markets. The formation of CapForce and its joint venture with ECIB positions the company to capitalize on the growing digital transformation within investment banking and cross-border trading, especially in Asia. This shift moves OpGen into a highly competitive, yet potentially lucrative, sector distinct from its previous life sciences focus.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer, Chairman, Director | David E. Lazar | John Tan Honjian | August 2024 | Mr. Lazar resigned after selling Series E Preferred Stock to AEI Capital Ltd. |
| President | NA | David E. Lazar | August 2024 | Retained a role as President after resigning from CEO/Chairman/Director. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board of Directors Composition | Members of the Board of Directors resigned, and a new Board was appointed in March 2024, with David E. Lazar as Chairman. Subsequently, Mr. Lazar resigned as Chairman in August 2024, and John Tan Honjian was appointed Chairman. | March 2024 and August 2024 | Reflects a change in control and strategic direction following the AEI Capital Ltd. transactions. |
| Equity Incentive Plan | No additional grants may be made under the 2015 Equity Incentive Plan after April 1, 2025, its ten-year anniversary. | 2025-04-01 | Limits future equity compensation grants under this specific plan, potentially requiring a new plan or alternative compensation methods. |
Legal Proceedings
- To the best of our knowledge, we are not currently a party to any legal proceedings that, individually or in the aggregate, are deemed to be material to our financial condition or results of operations.
Related Party Transactions
- AEI Capital Ltd. (controlling stockholder) is providing ongoing financing through a Securities Purchase Agreement, allowing the company to sell up to $7.0 million in common stock.
- CapForce earned $4.0 million in equity proceeds from a privately held client for listing sponsorship services, where the CEO of AEI Capital Ltd. and OpGen, Inc. serves as a member of the Board of Directors of the client.
- David E. Lazar, former CEO and Chairman, sold Series E Preferred Stock and rights to purchase additional shares to AEI Capital Ltd.
Stakeholder Impact
- Shareholders: Significant increase in net income and revenue is positive, but Nasdaq delisting and trading on OTC Expert Market may reduce liquidity and investor confidence. Potential dilution from future common stock sales to AEI Capital Ltd.
- Employees: Repositioning involved scaling down legacy operations, implying potential workforce adjustments in the past, but new ventures like CapForce and the JV may create new opportunities.
- Customers: New focus on listing sponsorship and digital investment banking services through CapForce, shifting away from previous precision medicine customers.
- Creditors: Settlement of EIB debt in August 2024 resolved a significant liability. Ongoing short-term insurance financing.
Next Steps
- Fund operations primarily through financing arrangements with AEI Capital Ltd.
- Apply for relisting with The Nasdaq Stock Market LLC after meeting relevant listing requirements.
- Develop and operate a stock trading platform and digital investment banking platform through the CapForce EC Capital Markets Ltd. joint venture.
- Evaluate the effects of new accounting standards (ASU No. 2025-05, ASU 2025-06, ASU 2025-07) on financial statements.
Key Dates
| Date | Description |
|---|---|
| 2001 | OpGen, Inc. incorporated in Delaware. |
| 2015-04 | Company adopted 2015 Equity Incentive Plan. |
| 2015-05 | 2015 Equity Incentive Plan became effective upon execution of underwriting agreement for initial public offering. |
| 2016 | Curetis entered into a loan financing facility from the European Investment Bank (EIB). |
| 2020-04-01 | OpGen completed business combination transaction with Curetis N.V. |
| 2020-07-09 | Guarantee and Indemnity Agreement between EIB and OpGen, Inc. signed. |
| 2023-10 | Company entered into a Preferred Stock Purchase Agreement (October 2023 Purchase Agreement) with a single investor. |
| 2023-11 | Curetis and Ares Genetics filed petitions for insolvency; investor funded $250,000 of October 2023 Purchase Agreement. |
| 2023-12 | Company received notice from EIB stating Curetis was in default and demanding repayment. |
| 2024-01-02 | AEI Capital Ltd. entered into Letter of Engagement with a privately held company (the Client) for listing advisory services. |
| 2024-03 | Company entered into March 2024 Purchase Agreement with David E. Lazar; Mr. Lazar paid $200,000 for 200,000 shares of Series E Preferred Stock; Company entered into settlement agreements with EIB and Curetis; Company entered into Inducement Offer to Amend Common Stock Purchase Warrants. |
| 2024-04 | Company entered into employment agreement with Mr. Lazar as CEO; Curetis assets sold to Camtech Pte Ltd.; Ares Genetics assets sold to bioMerieux S.A.; Mr. Lazar paid $350,000 for additional 350,000 shares of Series E Preferred Stock. |
| 2024-05 | Stockholder approval for issuance of common stock to Mr. Lazar upon conversion of Series E Preferred Stock. |
| 2024-05-20 | Company effected a 1-for-10 reverse stock split. |
| 2024-06-05 | Company received letter from Nasdaq regarding non-compliance with minimum stockholders equity requirement. |
| 2024-07 | Mr. Lazar sold 550,000 shares of Series E Preferred Stock and rights to purchase additional shares to AEI Capital Ltd. |
| 2024-08 | AEI Capital Ltd. paid $2.45 million for remaining Series E Preferred Stock; all 3,000,000 shares of Series E Preferred Stock converted into 7,200,000 shares of common stock; Mr. Lazar resigned as CEO, Chairman, and Director, effective August 2024; Company paid and settled outstanding indebtedness with EIB and Curetis; Company entered into August 2024 Securities Purchase Agreement with AEI Capital Ltd. |
| 2024-08-16 | Company received letter from Nasdaq Hearings Panel denying request for continued listing. |
| 2024-08-20 | Suspension of trading on Nasdaq Capital Market at opening of business (stayed by appeal). |
| 2024-09-13 | Company submitted appeal regarding Nasdaq Panel's determination to the Nasdaq Listing and Hearing Review Council. |
| 2024-09-30 | No shares of Series E Preferred Stock remained outstanding. |
| 2024-10 | Company and AEI Capital Ltd. entered into a First Amendment to the August 2024 Securities Purchase Agreement. |
| 2024-12-19 | Nasdaq Listing Council affirmed the decision of the Panel to delist. |
| 2025-04-01 | No additional grants may be made under the 2015 Equity Incentive Plan. |
| 2025-04-03 | CapForce entered into a Joint Venture Agreement with European Credit Investment Bank (ECIB). |
| 2025-05 | Company entered into an agreement to finance a portion of its D&O insurance premium for May 2025 through May 2026. |
| 2025-06-30 | End of current reporting period. |
| 2025-07 | Maturity of lease liabilities begins for the period July to December 2025. |
| 2025-08-08 | Nasdaq filed a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission, removing the Company's securities from listing on Nasdaq. |
| 2025-10-31 | Date of issuance of the unaudited condensed consolidated financial statements. |
| 2025-12-31 | Extended ability to sell shares of common stock to AEI Capital Ltd. under the August 2024 Securities Purchase Agreement. |
| 2026-12-31 | Effective date for ASU No. 2025-05: Financial Instruments-Credit Losses. |
| 2027-12-31 | Effective date for ASU 2025-07 (share-based noncash consideration from a customer in a revenue contract). |
| 2028-12-31 | Effective date for ASU 2025-06 (Intangibles Goodwill and Other Internal-Use Software). |
Recommendation
holdWhile OpGen's strategic pivot to financial services and technology has resulted in a remarkable turnaround to profitability and substantial revenue growth in Q2 2025, the recent delisting from Nasdaq to the OTC Expert Market introduces significant liquidity and market perception challenges. The company's reliance on its controlling shareholder, AEI Capital Ltd., for future funding and the high customer concentration in its new business segment present additional risks. The long-term success of the new FinTech ventures and the ability to relist on a major exchange are critical but uncertain. Given the strong financial performance in the new segment balanced against significant market and operational risks, a 'hold' recommendation is appropriate for investors to observe the execution of the new strategy and address the delisting situation before making further commitments.
Keywords
OpGen, CapForce, Financial Technology, FinTech, Digital Investment Banking, Listing Sponsorship, SEC Filing, 10-Q, Quarterly Report, AEI Capital Ltd., Nasdaq Delisting, OTC Markets, Joint Venture, European Credit Investment Bank, ECIB, Corporate Repositioning, Revenue Growth, Profitability, Strategic Shift
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.